Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
New 3D Maps Reveal The Human Genome's Hidden Architecture
Research & Development New 3D Maps Reveal The Human Genome's Hidden Architecture

Deep within the microscopic confines of every human cell, a biological masterpiece unfolds not as a simple string of code but as a dynamic, three-dimensional sculpture that dictates life itself. A landmark study has now provided the most detailed and extensive atlas of this hidden architecture,

What Do New MA Telehealth Rules Mean for You?
Tech & Innovation What Do New MA Telehealth Rules Mean for You?

The landscape of virtual healthcare has entered a new and complex phase, where the rules governing patient access and provider reimbursement are no longer uniform across the board. In a significant move that underscores a growing divergence from federal guidelines, UnitedHealthcare announced on

Is a Molecular Gatekeeper the Next Cancer Target?
Research & Development Is a Molecular Gatekeeper the Next Cancer Target?

For decades, the cellular machinery responsible for building life’s essential proteins was viewed as a simple, unguided assembly line, but new evidence suggests a sophisticated manager has been overseeing the entire operation all along. This molecular coordinator, known as the nascent

Awareness Campaign Leads to Early Cancer Diagnosis in Nigeria
Research & Development Awareness Campaign Leads to Early Cancer Diagnosis in Nigeria

In the complex landscape of global health, few challenges are as daunting as tackling late-stage cancer diagnoses in regions with limited resources. Ivan Kairatov, a biopharma expert whose work sits at the intersection of technological innovation and public health, has been at the forefront of a

EMA Cites Breakthrough Drugs and Landmark EU Reforms
Biotech & Bioprocessing EMA Cites Breakthrough Drugs and Landmark EU Reforms

The European health sector is currently navigating a period of unprecedented transformation, where landmark legislative reforms and a surge in therapeutic innovation are converging to redefine the future of medicine regulation. As the European Medicines Agency (EMA) marks its 30th anniversary, it

Will Patient Deaths Derail Merck's New Cancer Drug?
Research & Development Will Patient Deaths Derail Merck's New Cancer Drug?

The cutting edge of cancer treatment often involves a delicate and high-stakes balance between revolutionary efficacy and severe, sometimes fatal, side effects. This reality has been starkly highlighted as a pivotal late-stage clinical trial for a promising new cancer therapy, ifinatamab deruxtecan

USD Med School Research Transforms South Dakota Health
Research & Development USD Med School Research Transforms South Dakota Health

In the quiet landscape of South Dakota, a veteran who had endured years of unrelenting chronic pain alongside the invisible wounds of post-traumatic stress disorder found an unexpected and complete reprieve, not from a new pill or surgical procedure, but from a low-level electrical current gently

Cheaper Health Plans Come With Hidden Risks
Research & Development Cheaper Health Plans Come With Hidden Risks

For millions of Americans navigating the annual health insurance marketplace, the stark reality of rising premiums forces a difficult calculation between financial solvency and physical well-being. This yearly ritual has become a high-stakes balancing act, where the allure of a lower monthly

Urinary MicroRNA Aging Clock – Review
Research & Development Urinary MicroRNA Aging Clock – Review

The longstanding quest to measure the true pace of human aging, independent of the calendar, has taken a decisive turn with the development of a biomarker that can be read from a simple urine sample. The development of the urinary microRNA (uEV-miRNA) aging clock represents a significant

Flow Chemistry, AI, and NMR Redefine API Production
Tech & Innovation Flow Chemistry, AI, and NMR Redefine API Production

At the forefront of pharmaceutical innovation, Ivan Kairatov is reimagining how essential medicines are made. As a leading expert in biopharma, his work merges the precision of continuous flow chemistry with the intelligence of advanced AI and real-time analytics. In a landscape reshaped by global

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later